NVAX - Novavax is one of the main contenders in the race for a Coronavirus Vaccine. This morning the company announced they have received $1.6 Billion in funding from the government under Operation Warp Speed. The funding will aid in the Phase 3 clinical trials of their vaccine candidate, NVX-CoV2373, and include up to 30,000 patients this Fall. Their goal is to also utilize the funding to scale-up manufacturing and delivery of the vaccine as early as late 2020. Shares are up 40% as of this post, and could continue to rise throughout the day. Watch for strong pull-backs and profit-taking, but also good entry-points for quick scalps and a short-term to intermediate hold.
TSLA - Still running off of momentum from last week's deliveries beat. Many investors are awaiting earnings and a milestone announcement of the company being included in the S&P 500.
Disclaimer: This post represents my own opinion and is not a substitute for professional investment advice. It does not represent a solicitation to buy or sell any security. Investors should conduct their own due diligence and consult their tax and financial advisors before making any investment.
Disclosure: I currently hold a position in: NVAX, TSLA, with the intention of going Intermediate and Long, respectively.
I wrote this post myself, and it expresses my own opinions while sometimes quoting others. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.